33 withdrawn. 33 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Withdrawn 33 |
| Phase 1 | 6 | Withdrawn 6 |
| Phase 3 | 3 | Withdrawn 3 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) - Major Depressive Disorder | Phase 2 | Withdrawn | National Institute of Mental Health (NIMH) | 2026-04-25 | 2026-04-28 | |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression | Phase 2 / Phase 3 | Withdrawn | Washington University School of Medicine | 2025-10-15 | 2025-10-29 | |
| Repeated Neurocognitive Measurements in Depressed Patients Intravenous Ketamine - Depression, Unipolar | Phase 1 / Phase 2 | Withdrawn | Jay Fournier | 2025-05-01 | 2026-02-25 | |
| Psilocybin for Major Depressive Disorder Psilocybin - Major Depressive Disorder | Phase 2 | Withdrawn | Washington University School of Medicine | 2024-01-01 | 2024-07-25 | |
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder Inositol - Bipolar Disorder, Anxiety Disorders | Phase 1 / Phase 2 | Withdrawn | Ronald M. Glick, MD | 2023-08-01 | 2023-10-06 | |
| PET Synaptogenesis After Psilocybin In DEpression Recovery Psilocybin - Major Depressive Disorder, Anhedonia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-07-01 | 2023-01-30 | |
| Effect of SSRIs on Response to Psilocybin Therapy Psilocybin - Depression, Major Depressive Disorder | Phase 2 | Withdrawn | Cybin Therapeutics Inc. | 2023-01-01 | 2023-07-06 | |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD Psilocybin - Treatment-Resistant Major Depressive Disorder | Phase 2 | Withdrawn | Massachusetts General Hospital | 2022-09-15 | 2024-01-24 | |
| The Efficacy of Probiotic Compared With Placebo Commitment Therapy for Treatment of Major Depressive Disorder Probiotic, Placebo, Acceptance and commitment therapy (ACT) - Major Depressive Disorder | Phase 2 | Withdrawn | Min-Tze LIONG | 2021-10-01 | 2023-05-10 | |
| The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients Tadalafil 5Mg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-08-01 | 2025-07-14 | |
| Antidepressant Effects of Nitrous Oxide Nitrous oxide gas for inhalation, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | Withdrawn | University of Chicago | 2021-06-30 | 2026-05-14 | |
| The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients Roflumilast 500Mcg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-02-01 | 2025-07-14 | |
| The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients Vildagliptin 50 MG, Escitalopram 20 mg - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2020-05-01 | 2025-07-14 | |
| Neural and Antidepressant Effects of Propofol (Phase 2) Diprivan - Treatment Resistant Depression | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2019-04-16 | 2019-12-18 | |
| Efficacy and Safety of TAK-653 in Treatment-Resistant Depression TAK-653, Placebo - Treatment-Resistant Depression | Phase 2 | Withdrawn | Millennium Pharmaceuticals, Inc. | 2018-02-15 | 2018-02-22 | |
| Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine Lithium, Placebo, Ketamine - Treatment Resistant Depression | Phase 2 | Withdrawn | William V. Bobo, M.D. | 2017-11-30 | 2018-08-16 | |
| Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression Valproate and Placebo, Valproate and Cytidine-containing Drug, Valproate and Creatine-containing Drug - Depression, Bipolar | Phase 2 | Withdrawn | Ewha Womans University Mokdong Hospital | 2016-03-01 | 2018-02-09 | |
| Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression Valproate+Cytidine-+Creatine-, Valproate+Cytidine-, Valproate - Bipolar Depression | Phase 2 | Withdrawn | Ewha Womans University | 2015-12-01 | 2018-02-09 | |
| Trial of Ketamine and Lithium Therapy in Bipolar Depression Placebo, Ketamine, Ketamine/Lithium - Bipolar Depression | Phase 2 | Withdrawn | Yale University | 2013-01-01 | 2023-03-01 |
Showing 20 of 33. Sign in to see all of them.
Depressive Disorder, Major (16) · Bipolar Disorder (11) · Depression (11) · Depressive Disorder, Treatment-Resistant (6) · Depressive Disorder (3) · Anhedonia (1) · Anxiety Disorders (1) · Depression, Postpartum (1) · Mental Disorders (1) · Rumination Syndrome (1) · Stress Disorders, Post-Traumatic (1) · Suicidal Ideation (1)
Mental Disorders (32) · Depressive Disorder (20) · Behavior (11) · Behavioral Symptoms (11) · Bipolar and Related Disorders (11) · Digestive System Diseases (1) · Feeding and Eating Disorders (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Pregnancy Complications (1)
Ketamine (4) · Psilocybin (4) · Transcranial Magnetic Stimulation (3) · Endothelium-Dependent Relaxing Factors (2) · Inhalation (2) · Lithium (2) · Nitrous Oxide (2) · Valproic Acid (2) · 1-(benzofurazan-5-ylcarbonyl)piperidine (1) · AMPA receptor potentiator HBT1 (1) · Acceptance and Commitment Therapy (1) · Ceftriaxone (1) · Creatine (1) · Cytidine (1) · Deep Brain Stimulation (1)
National Institute of Mental Health (NIMH) (3) · Sadat City University (3) · Washington University School of Medicine (3) · Ewha Womans University (2) · University of Chicago (2) · Cybin Therapeutics Inc. (1) · Dennis Charney (1) · Ewha Womans University Mokdong Hospital (1) · Jay Fournier (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · Millennium Pharmaceuticals, Inc. (1) · Min-Tze LIONG (1) · Ronald M. Glick, MD (1) · Stanford University (1)
United States (16) · Egypt (3) · South Korea (3) · Australia (2) · Canada (2) · Germany (1) · Malaysia (1)
Peter Nagele, MD, MSc (2) · Allan Young, MD (1) · Chadi Abdallah, MD (1) · Charles DeBattista, DMH, MD (1) · Colleen Loo, FRANZCP, MD (1) · Daniel S Pine, M.D. (1) · David Monks, MBCHB (1) · Dennis S Charney, MD (1) · F. Andrew Kozel, MD, MSCR (1) · Ginger Nicol, MD (1) · In Kyoon Lyoo, MD, PhD, MMS (1) · Inkyoon Lyoo, MD, PhD, MMS (1) · Irving Reti, M.B.B.S (1) · Luke Woon Sy-Cherng, Dr (1)
2017 (1), R25MH112473 (1), T32DA022975 (1)